Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | GSK3A | P49840 | 1/20 | 0.50 |
| ▸ | GSK3B | P49841 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL27986613 | 0.93 | TSHR (0.50) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL4600179 | 0.90 | TSHR (0.52) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL23077911 | 0.81 | TSHR (0.44) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL121100 | 0.81 | TSHR (0.40) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL1269478 | 0.80 | RAB9A (0.42) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL25890753 | 0.80 | HSD17B10 (0.41) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL5002371 | 0.78 | SMN1; SMN2 (0.56) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL6037020 | 0.77 | SMN1; SMN2 (0.43) | TSHRKMT2AMEN1GSK3AGSK3B | |
| SCHEMBL5091798 | 0.77 | TSHR (0.44) | TSHRKMT2AMEN1SMN1; SMN2RAB9A | |
| SCHEMBL7773775 | 0.77 | SMN1; SMN2 (0.43) | TSHRKMT2AMEN1GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 775 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027176-B | Human beta 2-microglobulin mutant | 郑春杨 | 2024-12-24 | — | — | CN | claimed |
| CN-118027176-A | Human beta 2-microglobulin mutant | 郑春杨 | 2024-05-14 | — | — | CN | claimed |
| CN-117603335-A | Human serum amyloid A mutant | 北京春雷杰创生物科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-117486998-A | Dipolyethylene glycol-insulin conjugate and preparation method and application thereof | 中山大学 | 2024-02-02 | — | — | CN | claimed |
| CN-116183763-A9 | Impurity detection method of piracetam injection | 北京星昊盈盛药业有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-116867795-A | Novel method for producing antibody-immunostimulant conjugate | 第一三共株式会社 | 2023-10-10 | — | — | CN | claimed |
| WO-2023129438-A1 | HYDROGEL COMPOSITIONS FOR USE FOR DEPLETION OF TUMOR ASSOCIATED MACROPHAGES | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-07-06 | — | — | WO | claimed |
| CN-109810198-B | Site-specific GLP-2 conjugates utilizing immunoglobulin fragments | 韩美科学株式会社 | 2023-06-06 | — | — | CN | claimed |
| CN-116183763-A | Impurity detection method of piracetam injection | 北京星昊盈盛药业有限公司 | 2023-05-30 | — | — | CN | claimed |
| US-20230090790-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | HANMI PHARM. CO., LTD. (KR) | 2023-03-23 | — | — | US | claimed |
| US-20040180054-A1 | Physiologically active polypeptide conjugate having prolonged in vivo half-life | HANMI PHARM. CO., LTD. | 2004-09-16 | — | — | US | claimed |
| WO-2003070805-A1 | HYDROLYTICALLY DEGRADABLE ALKYLENE OXIDE BASED POLYMERS | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| US-20030023023-A1 | Hydrolytically degradable polymers and hydrogels made therefrom | SHEARWATER CORPORATION | 2003-01-30 | — | — | US | claimed |
| EP-0792893-B1 | Polyolefins modified with an unsaturated polyfunctional monomer containing an imide group and an ester group | POLIMERI EUROPA SPA (IT) | 2002-07-17 | — | — | EP | claimed |
| US-6348558-B1 | OLIGOMERS COMPRISING ALKYLENE OXIDE MONOMERS AND CARBONATE LINKAGES; POLYCARBONATEETHER COPOLYMERS; DRUG DELIVERY; CONJUGATED TO PEPTIDES OR PROTEINS FOR REDUCED IMMUNOGENICITY; STABILITY | SHEARWATER CORPORATION | 2002-02-19 | — | — | US | claimed |
| EP-0366041-B2 | Imido-percarboxylic acids | AUSIMONT SPA (IT) | 2001-09-12 | — | — | EP | claimed |
| US-5817720-A | GRAFT POLYMERS | ENICHEM S.P.A. (IT) | 1998-10-06 | — | — | US | claimed |
| EP-0366041-B1 | Imido-percarboxylic acids | AUSIMONT SPA (IT) | 1998-08-05 | — | — | EP | claimed |
| EP-0792893-A2 | Polyolefins modified with an unsaturated polyfunctional monomer containing an imide group and an ester group | ENICHEM S.p.A. (IT) | 1997-09-03 | — | — | EP | claimed |
| EP-0366041-A2 | Imido-percarboxylic acids | AUSIMONT S.r.l. (IT) | 1990-05-02 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230090790-A1 | LONG-ACTING CONJUGATES OF GLP-2 DERIVATIVES | GIPR, VIP, GLP1R | TSHR 528/4885KMT2A 2059/4885MEN1 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.